Today, I review, link to and excerpt from Pharmacological thiamine levels as a therapeutic approach in Alzheimer’s disease [PubMed Abstract] [Full-Text HTML] [Full-Text PDF]. Front Med (Lausanne). 2022; 9: 1033272.
Published online 2022 Oct 4. doi: 10.3389/fmed.2022.1033272
There are 101 similar articles in PubMed.
The article has been cited by 7 articles in PubMed.
All that follows is from today’s resource.
Graphical Abstract
Summary of the study.
Keywords: thiamine, Alzheimer’s disease, benfotiamine, Advanced Glycation Endproducts (AGE), glucose metabolism, cognition, therapy
Evidence linking abnormalities in thiamine (vitamin B1) availability and metabolism to the pathophysiology of Alzheimer’s Disease (AD) has focused attention on the regulation of thiamine as a therapeutic target. A recently completed pilot clinical trial in AD patients revealed that increasing blood thiamine to pharmacologically high levels using benfotiamine has potential efficacy in treating persons with early AD. These results support the underlying hypothesis that thiamine insufficiency promotes AD and is a druggable target. A mechanistic understanding of thiamine’s cellular actions and improved methods to deliver thiamine to the brain are fundamental to optimize the use thiamine homeostasis as a target of engagement. Benfotiamine has a therapeutic product profile in AD that includes raising blood thiamine to pharmacologically high levels, with excellent safety and potential for clinical efficacy. It is a potentially widely available treatment.
